Using silver nanoparticles, researchers create cream that avoids the transmition of HIV

January 28, 2014
Silver nanoparticles.

After discovering that silver nanoparticles are capable of blocking the entry of Human Immunodeficiency Virus (HIV) into the organism, a group of researchers from the University of Texas, in collaboration with Humberto Lara Villegas, specialist in nanoparticles and virology from the University of Monterrey, Mexico (UDEM), created a vaginal cream to control the transmition of the virus.

Lara Villegas explains that HIV makes its entry to (CD4) of the organism with the aid of a protein known as GP120, which allows the virus adherence to the cells. This same principle is used by to attach themselves to this protein and block it, turning the virus inactive.

The Mexican researcher says that the cream has been tested in samples of human tissue and has proven the efficiency of silver nanoparticles to avoid the transmition of the virus through cervical mucous membrane.

The researcher from UDEM, who has worked in Israel and The United States, says that after applied, the cream starts to work in less than a minute, and has an effective protection of up to 72 hours.

Given that the function of this product is the inactivation of the virus, although this is a vaginal cream, will also protect the sexual partner.

"Normally, the medication used against the virus acts within the cell to prevent its replication. This is a very different case, given that the nanoparticle goes directly against the HIV and no longer allows its entry to the cell."

Silver nanoparticles.

So far, no toxicity of the silver nanoparticles has been reported, although he adds that research has yet to be performed to evaluate the possible side effects of silver properties. "Right now, I am certain that this microbicide is going to prevent the virus entering the organism, but I cannot yet assure that is totally harmless, because the clinical trials are a long and expensive process," he says.

He adds that the use of gels is usually accompanied by irritation, which favors the entry of the , which is why the cream was enriched with an anti-inflammatory.

Next, with the obtained results, researchers will perform experimentation in mice that accept human cells, with human later.

He says that this cream could prevent the transmition of other sexually acquired viruses like the Human Papilloma Virus (HPV). Additionally, he says that nanoparticles could be used to combat bacteria transmitted the same way.

He says that his research team is working on a diagnosis kit that predicts within hours, through blood tests, the resistance of a seropositive person to antiretroviral treatment, results that will help the physician to prescribe the most adequate treatment to patients with HIV.

"Currently, we have these results, but they are preliminary tests and we need to study a lot of seropositive patients to calibrate this kit," he concluded.

Explore further: Vaginal microbicide gel may offer a promising strategy for prevention and protection against HIV transmission

Related Stories

Vaginal microbicide gel may offer a promising strategy for prevention and protection against HIV transmission

December 6, 2012
A new study shows that a microbicide gel is highly effective in block infection by the AIDS virus in a non-human primate model. In the paper published December 6 in the Open Access journal PLOS Pathogens, Dereuddre-Bosquet ...

New anti-HIV drug target identified

December 18, 2013
University of Minnesota researchers have discovered a first-of-its-kind series of compounds possessing anti-human immunodeficiency virus (HIV) activity. The compounds present a new target for potential HIV drug development ...

Viral replication may not be primary cause of HIV-1 persistence in patients receiving cART

November 26, 2013
(Medical Xpress)—A team of researchers with members from Europe and the U.S. has found that viral replication may not be the main reason that the HIV virus is able to persist in the cells of infected patients for many years. ...

Nanoparticles loaded with bee venom kill HIV

March 8, 2013
(Medical Xpress)—Nanoparticles carrying a toxin found in bee venom can destroy human immunodeficiency virus (HIV) while leaving surrounding cells unharmed, researchers at Washington University School of Medicine in St. ...

Study identifies population of stem-like cells where HIV persists in spite of treatment

January 12, 2014
Although antiviral therapy against HIV suppresses viral replication and allows infected individuals to live relatively healthy lives for many years, the virus persists in the body, and replication resumes if treatment is ...

Recommended for you

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around ...

Research finds home-based kit would increase HIV testing

July 31, 2017
Research led by William Robinson, PhD, Associate Research Professor of Behavioral & Community Health Sciences at LSU Health New Orleans School of Public Health, has found that 86% of heterosexuals who are at high risk for ...

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.